



FACULTY OF MEDICINE AND HEALTH SCIENCES
HEYMANS INSTITUTE OF PHARMACOLOGY

Regulatory - Clinical Methodologies For Medical Device Clinical Trials

Thesis submitted for the fulfilment
of the requirements for the
Degree of Doctor in Social Health Sciences: Medical-Social Sciences



Herman Pieterse
2008

Promotors: Prof. dr. LM Van Bortel and Prof. dr. P van Cauwenberge

Table of Contents

List of abbreviations	10
Glossary of terms	13
Preface	27
Chapter 1 The Regulatory Environment	31
1.0. Introduction	32
2.0 Compliance criteria	32
2.1 Manufacturer	35
2.2 Medical device	36
2.3 Classification	39
2.4 Intended Use.....	40
2.5 Substantial equivalence	40
2.6 Essential requirements	40
2.7 Risk analysis	43
2.8 Clinical evidence	43
Critical clinical evaluation	44
Clinical evidence from clinical trials	45
Summary.....	46
2.9 Labelling requirements.....	46
2.10 Conformity assessment	48
2.11 Medical device vigilance or adverse events reporting	49
3.0 Scientific aspects of compliance	50
4.0 Conclusions	51
Chapter 2 The Biomedical Ethics Environment	61
1.0 Introduction	62
2.0 Basic Principles of the global rules	63
2.1 Data Protection	67
3.0 Flow for a medical device trial	68
4.0 Responsibilities and accountability	68
4.1. Sponsor.....	68
4.2. Investigator	69
4.3. Monitor.....	69
4.4. Auditor.....	73

4.5	Ethics Committee.....	73
4.6	Trial subjects.....	74
4.7	Competent authority.....	75
5.0	Documentation.....	76
5.1.	Quality system documents.....	77
5.2.	Trial documents.....	78
5.3.	Record keeping.....	80
6.0.	Informed consent.....	81
6.1.	Witnessed informed consent.....	82
6.2.	Vulnerable trial subjects and informed consent.....	83
6.3.	Missing/Forgotten informed consent.....	83
7.0	Adverse events.....	83
8.0	Insurance Coverage.....	84
8.1.	Factors Related To Insurance.....	85
8.2	Types of Insurance.....	85
9.0	Quality control issues.....	86
10.0	Regulatory non-compliance issues.....	90
11.0	Conclusions.....	91
Chapter 3	The Methodology.....	97
1.0	Introduction.....	98
2.0	Definitions.....	98
2.1	Bias.....	99
2.2	Blind review.....	99
2.3	Double-dummy.....	99
2.4	Intention-To-Treat.....	99
2.5	Per Protocol Analysis.....	100
2.6	Full Analysis Set.....	100
2.7	Multi-centre Trial.....	100
3.0.	Bias minimisation.....	100
3.1	Randomisation.....	100
3.2	Blinding.....	101
3.3	Placebo studies.....	103
4.0	Clinical trial designs.....	105
4.1	Longitudinal.....	105

Prospective studies	105
Retrospective studies.....	106
Observational studies.....	106
Cross sectional.....	107
Comparative controlled.....	108
Parallel group.....	109
Crossover.....	110
5.0 Conclusions.....	112
Chapter 4 The Migraid® study.....	115
1.0 Introduction.....	116
2.0 Regulatory and GCP aspects.....	116
2.1 Regulatory aspects.....	116
2.2. Medical Community Perceptions.....	117
2.3 Study design.....	118
2.4. Biomedical requirements.....	119
Clinical trial documentation and process preparation.....	120
Selection and recruitment of the trial sites.....	120
Insurance.....	121
Medical device vigilance issues.....	121
Approval/authorisation.....	121
Preparation of the trial sites including training.....	121
Monitoring, data collection, data management.....	122
3.0. Summary of the trial findings.....	122
4.0 Background of the trial.....	122
5.0 Patients and methods.....	123
5.1 Study design.....	123
5.2 Patients.....	123
5.3 Methods.....	124
6.0 Statistical analysis.....	124
7.0 Results of the trial.....	125
8.0 Discussion.....	132
9.0 Side Effects/ Adverse events.....	134
10.0 Post-study follow-up.....	134

11.0 Conclusions	135
Chapter 5 Future developments	137
1.0 Introduction	138
2.0 Key issues with the current regulatory system	138
2.1 Law- and decision-making process.....	139
2.2 Alignment of requirements.....	139
2.3 Notified body issues.....	139
2.4 Competent authority surveillance and enforcement.....	140
2.5 Medical Economics.....	141
3.0 Future regulatory process	141
3.1 Data exchange networks.....	144
3.2 Recasting the regulatory process.....	145
Conformity assessment.....	145
Clinical trials.....	146
Device trial.....	146
Trial locations.....	147
Publication of clinical data.....	148
Post-market surveillance and Medical device vigilance.....	149
Market surveillance.....	149
3.3. Electronic patient medical dossiers or medical records.....	149
3.4. Performance of healthcare institutions.....	150
4.0 Conclusions	150
Summary	152
Samenvatting in het Nederlands	155
Acknowledgements	159
About the Author	161
Bibliography / References	163
First Author publications	174

Tables and Figures

Table 1	Summary of major essential requirements	41
Table 2	Labelling requirements for medical devices	47
Table 3	Summary of Regulatory Requirements per Country	53
Table 4	Summary overview of common biomedical requirements	64
Table 5	Responsibilities of the key parties under GCP	71
Table 6	Ethics Committee's Responsibilities	74
Table 7	Rights of the Subjects	75
Table 8	Overview of standard operating procedures for institutions conducting trials.....	77
Table 9	Clinical trial documentation ²⁰	78
Table 10	Clinical trial record keeping	81
Table 11	Medical device trial audits overview	87
Table 12	Overview of cardiovascular medical device studies audits	89
Table 13	Summary of Global GCP Requirements per Country	92
Table 14	Classification of clinical trial designs ¹⁰	105
Table 15	Essential requirements relevant to the Migraid	117
Table 16	Patient characteristics and migraine history data	125
Table 17	Primary efficacy parameter: proportion of pain-free attacks after 120 min.....	126
Table 18	Use of Rescue Medication	127
Table 19	Results of post-study follow-up	135
Figure 1	Flowchart conducting medical device trials.....	70
Figure 2	Flowchart Parallel Design.....	110
Figure 3	Flowchart Crossover Design.....	111
Figure 4	Trial subjects with severe headache – Observed case approach.....	128
Figure 5	Flow diagram of study population.....	129
Figure 6	Trial subjects with severe headache –Last Observation Carried Forward approach.....	130
Figure 7	Difference in headache severity score.....	131
Figure 8	Trial subjects with nausea: Observed case approach.....	132